ArticleMolecular biology reports2026
Next-generation CD179a-CAR-T cells demonstrate potent and sustained anti-tumor activity in preclinical B-cell malignancies.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment landscape for B-cell malignancies, particularly in relapsed and refractory leukemia. However, conventional CAR constructs targeting CD19 or CD20 often result in off-tumor toxicity due to shared antigen expression on healthy B-cells. CD179a, a novel leukemia-associated antigen with limited expression on normal tissues, presents a promising alternative target for safer and more specific immunotherapy.
methodsA 5th-generation CAR construct targeting CD179a was engineered and transfected into human T-cells to assess its antileukemic efficacy. Functional characterization was performed using the JM1-VRL-10,423 B-cell leukemia cell line. Post-transfection, cytotoxic activity, apoptosis induction, gene expression, and tumor cell viability were quantified. To evaluate safety, CD179a-CAR T-cells were also co-cultured with normal human peripheral blood mononuclear cells (PBMCs). Additionally, the in vivo efficacy of CD179a-directed CAR T-cells was tested in a xenograft model of B-cell leukemia, using mice transplanted with CD179a+ tumor cells.
resultsIn vitro, CD179a-targeted CAR T-cells demonstrated potent cytotoxicity, reducing leukemia cell viability to 44.22% after 72 h, superior to both CD3/CD28-activated T-cells and 5-Fluorouracil (5-FU). Apoptosis assays confirmed early apoptotic induction in 54.3% of leukemia cells. Importantly, negligible cytotoxic effects were observed in PBMCs, indicating selective targeting. In the xenograft model, CD179a-CAR T-cells significantly reduced the expression of CD179a in leukemic cells compared to controls. Gene expression profiling further validated apoptosis pathway activation.
conclusionThese findings highlight the promising antileukemic potential of CD179a-directed CAR T-cells, combining high specificity with a favorable safety profile. This in vitro and in vivo study supports the advancement of CD179a-CAR T-cell therapy as a next-generation immunotherapeutic strategy for B-cell leukemias, warranting further preclinical and clinical development.
Indexed as
Identifiers
42047877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.